Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
Xiang SongJian GongXiaoling ZhangXiaoyan FengHui HuangMin GaoLi ChuPublished in: British journal of cancer (2020)
Our results indicate that dEGFR39 assay is reliable, sensitive and cost-efficient. This method is beneficial for profiling EGFR mutations for precision therapy and prognosis after TKI treatment, especially in patients with insufficient tissue biopsy samples.
Keyphrases
- small cell lung cancer
- tyrosine kinase
- epidermal growth factor receptor
- end stage renal disease
- high throughput
- advanced non small cell lung cancer
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- stem cells
- single cell
- patient reported outcomes
- mesenchymal stem cells
- combination therapy
- ultrasound guided
- replacement therapy